<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380197</url>
  </required_header>
  <id_info>
    <org_study_id>09-076</org_study_id>
    <nct_id>NCT01380197</nct_id>
  </id_info>
  <brief_title>Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>Choosing Opioid Management for Pain and Analyzing ACS Rates Equally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlanta Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Healthcare of Atlanta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of sickle cell disease (SCD) manifestations, are complex with
      interactions of intracellular hemoglobin, membrane and endothelial activation but the
      hallmark remains recurrent and painful vaso-occlusive episodes (VOC). These painful episodes
      are thought to result from ischemia caused when small blood vessels are occluded by
      misshapen, inflexible erythrocytes. Painful episodes are the most common cause of
      hospitalization, morbidity, and impairment for SCD patients. There is no therapy that
      completely prevents or directly aborts painful events for all patients. Consequently,
      treatment for acute VOC is primarily supportive using hydration and medicinal pain control.
      Every pain medication has the potential to relieve pain but is associated with significant
      limitations and side effects.

      The primary hypothesis to be tested in this double blind, randomized controlled trial is that
      Nalbuphine is equivalent to morphine for pain control and patients will suffer fewer episodes
      of acute chest syndrome. The investigators also expect subjects will report fewer side
      effects from respiratory depression, abdominal distention from reduced peristalsis, reduced
      histamine release causing pruritis and still be provided adequate pain control. Further
      hypotheses to be tested is ability to recruit patient participants while being treated in the
      Emergency Department and that continuous infusion of Nalbuphine with accompanying patient
      controlled analgesia (PCA) is safe and effective in controlling pain, requiring less total
      opiates consumption, while decreasing length of hospitalization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2010</start_date>
  <completion_date type="Actual">October 18, 2016</completion_date>
  <primary_completion_date type="Actual">January 14, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Chest Syndrome</measure>
    <time_frame>3 days</time_frame>
    <description>Number of Participants with Acute Chest Syndrome or A new pulmonry infiltrate on Chest X-ray</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Pain Relief</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Randomizing particiipants to Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomization to Nubain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
    <arm_group_label>Randomizing particiipants to Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nubain</intervention_name>
    <description>Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
    <arm_group_label>Randomization to Nubain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with sickle cell disease (SS, SC, SÎ²Thal) who are hospitalized for acute
             painful episodes

          -  6 years old and &lt; 19 years old

          -  Normal baseline chest radiograph

          -  Normal renal and hepatic function within the previous 12 months

        Exclusion Criteria:

          -  Previous patient participation in this clinical trial

          -  Any patient on chronic transfusion Any patient with pulmonary infiltrate on chest
             radiograph on admission

          -  Any patient with DSM diagnosis, excluding those with Attention Deficit Disorder, on or
             off treatment

          -  Any patient with documented allergy to either study drug

          -  Any patient with known evidence of an underlying disease that would interfere with
             evaluation of a therapeutic response such as:

               -  Hepatic dysfunction (3x ALT),

               -  Renal dysfunction (Cr &gt; 1 children/adolescents, Cr &gt;2 adults),

               -  Pulmonary Hypertension (TRJ &gt;3.0),

               -  Cardiac dysfunction.

               -  Any patient with symptoms of an acute stroke.

               -  Any patient known or suspected to be pregnant.

               -  Any patient with priapism

               -  The patient or guardian who will not give consent or assent to be randomized.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>February 2, 2015</results_first_submitted>
  <results_first_submitted_qc>February 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2015</results_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Healthcare of Atlanta</investigator_affiliation>
    <investigator_full_name>Saadia Khizer</investigator_full_name>
    <investigator_title>Iris Buchanan MD</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>sickle cell</keyword>
  <keyword>nubain</keyword>
  <keyword>morphine</keyword>
  <keyword>acute chest</keyword>
  <keyword>side effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Acute Chest Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Randomizing Particiipants to Morphine</title>
          <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
        <group group_id="P2">
          <title>Randomization to Nubain</title>
          <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomizing Particiipants to Morphine</title>
          <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
        <group group_id="B2">
          <title>Randomization to Nubain</title>
          <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Chest Syndrome</title>
        <description>Number of Participants with Acute Chest Syndrome or A new pulmonry infiltrate on Chest X-ray</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomizing Particiipants to Morphine</title>
            <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
          </group>
          <group group_id="O2">
            <title>Randomization to Nubain</title>
            <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Chest Syndrome</title>
          <description>Number of Participants with Acute Chest Syndrome or A new pulmonry infiltrate on Chest X-ray</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Pain Relief</title>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomizing Particiipants to Morphine</title>
            <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
          </group>
          <group group_id="O2">
            <title>Randomization to Nubain</title>
            <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Pain Relief</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Randomizing Particiipants to Morphine</title>
          <description>Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
Morphine: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
        <group group_id="E2">
          <title>Randomization to Nubain</title>
          <description>Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
Nubain: Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Iris Buchanan</name_or_title>
      <organization>Morehouse School of Medicine</organization>
      <phone>404-398-9578</phone>
      <email>ibuchanan@msm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

